Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma

Avinash Kambadakone; Vinit Baliyan; Andrew X. Zhu

doi:10.1055/s-0037-1606254

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2017; 37(03): 259-274
DOI: 10.1055/s-0037-1606254

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma

Authors

Avinash Kambadakone

¹Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Vinit Baliyan

¹Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Andrew X. Zhu

²Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Abstract

Increasing use of novel systemic treatment options in the management of patients with advanced hepatocellular carcinoma (HCC) such as antiangiogenic and molecular-targeted therapies, poses unique challenges for effective treatment monitoring and efficacy assessment. The traditional morphological criteria such as response evaluation criteria in solid tumor (RECIST) rely on changes in tumor size to determine treatment efficacy. However, these criteria based on tumor morphology may not be suitable to monitor response to newer targeted therapies as early functional changes induced by these drugs precede changes in tumor size. Modifications of these morphological criteria that determine response based on tumor enhancement characteristics such as modified RECIST (mRECIST) will potentially allow improved determination of treatment response pending validation from prospective trials. Advanced functional imaging techniques such as perfusion imaging (computed tomography/magnetic resonance imaging [CT/MRI]), diffusion weighted MRI (DW-MRI) and positron emission tomography (PET/CT and PET/MRI) are being increasingly used as surrogate imaging biomarkers to provide superior assessment of changes in tumor physiology. Growing emphasis on precision oncological care tailored to specific tumor type and individual patients renders the use of these newer imaging modalities more pertinent and timely. In this review, the authors discuss the role of various imaging techniques and response assessment criteria in the evaluation of systemic therapy for advanced HCC with focus on functional imaging tools.

Keywords

hepatocellular carcinoma - computed tomography - magnetic resonance imaging - systemic therapy - response assessment - RECIST - mRECIST

Full Text

References

References
1 Bertuccio P, Turati F, Carioli G. , et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 2017; S0168-8278(17)30145-9
2 Ferlay J, Soerjomataram I, Dikshit R. , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
3 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol 2013; 5 (06) 311-322
4 Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2014; 10 (03) 153-161
5 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 2012; 27 (05) 862-872
6 Llovet JM, Ricci S, Mazzaferro V. , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
7 Bruix J, Sherman M, Llovet JM. , et al; EASL Panel of Experts on HCC; European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35 (03) 421-430
8 Cheng A-L, Kang Y-K, Chen Z. , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
9 Cheng A. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). 2017 ASCO Annual Meeting Abstracts [Internet]. Available at: http://abstracts.asco.org/199/AbstView_199_186143.html . Accessed June 26, 2017
10 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48 (04) 1312-1327
11 Figueiras RG, Padhani AR, Goh VJ. , et al. Novel oncologic drugs: what they do and how they affect images. Radiographics 2011; 31 (07) 2059-2091
12 Kelley RK, Verslype C, Cohn AL. , et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol 2017; 28 (03) 528-534
13 Zhu AX, Park JO, Ryoo B-Y. , et al; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015; 16 (07) 859-870
14 Ikeda K, Kudo M, Kawazoe S. , et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017; 52 (04) 512-519
15 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60
16 Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 2013; 58 (01) 169-177
17 Van Beers BE, Daire J-L, Garteiser P. New imaging techniques for liver diseases. J Hepatol 2015; 62 (03) 690-700
18 Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted?. AJR Am J Roentgenol 2009; 193 (02) 304-313
19 Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol 2011; 197 (02) W256-9
20 Basik M, Aguilar-Mahecha A, Rousseau C. , et al. Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol 2013; 10 (08) 437-450
21 Eisenhauer EA, Therasse P, Bogaerts J. , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
22 Galizia MS, Töre HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol 2011; 18 (12) 1555-1560
23 Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014; 34 (04) 444-455
24 Horger M, Lauer UM, Schraml C. , et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer [Internet]. Available at: http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-9-208 . Accessed March 26, 2017
25 Chun YS, Vauthey J-N, Boonsirikamchai P. , et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302 (21) 2338-2344
26 Forner A, Ayuso C, Varela M. , et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009; 115 (03) 616-623
27 Boonsirikamchai P, Asran MA, Maru DM. , et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol 2011; 197 (06) W1060-6
28 Bruix J, Sherman M. ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42 (05) 1208-1236
29 Kudo M, Kubo S, Takayasu K. , et al; Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40 (07) 686-692
30 Llovet JM, Di Bisceglie AM, Bruix J. , et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (10) 698-711
31 Ronot M, Bouattour M, Wassermann J. , et al. Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; 19 (04) 394-402
32 Bruix J, Reig M, Sangro B. Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. J Hepatol 2017; 66 (06) 1114-1117
33 Uchino K, Tateishi R, Shiina S. , et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2011; 117 (19) 4475-4483
34 Lencioni R, Montal R, Torres F. , et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017; 66 (06) 1166-1172
35 Edeline J, Boucher E, Rolland Y. , et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118 (01) 147-156
36 Takada J, Hidaka H, Nakazawa T. , et al. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 2015; 8: 609
37 Arizumi T, Ueshima K, Takeda H. , et al. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol 2014; 49 (12) 1578-1587
38 Lencioni R, Raoul J-L, Park JW, Baudelet C, Walters I. Comparison of tumor responses by modified WHO and new RECIST criteria from a phase II study of first-line brivanib in hepatocellular carcinoma (HCC). J Clin Oncol [Internet]. Available at: http://meetinglibrary.asco.org/content/1758-72 . Accessed May 3, 2017
39 Johnson PJ, Qin S, Park J-W. , et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31 (28) 3517-3524
40 Bruix J, Qin S, Merle P. , et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10064): 56-66
41 Meyer T, Palmer DH, Cheng A-L, Hocke J, Loembé A-B, Yen C-J. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int 2017; 37 (07) 1047-1055
42 Edeline J, Palmer D, Blanc J-F, Campillo-Gimenez B, Merle P, Meyer T. mRECIST for systemic therapies: More evidence is required before recommendations can be made. J Hepatol 2017; 67 (01) 195
43 Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target?. Clin Cancer Res 2009; 15 (19) 5947-5949
44 Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010; 30 (06) 591-601
45 Llovet JM, Decaens T, Raoul J-L. , et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31 (28) 3509-3516
46 Cheng A-L, Kang Y-K, Lin D-Y. , et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31 (32) 4067-4075
47 Choi H, Charnsangavej C, de Castro Faria S. , et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183 (06) 1619-1628
48 Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47 (01) 11-17
49 Gavanier M, Ayav A, Sellal C. , et al. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1. Eur J Radiol 2016; 85 (01) 103-112
50 Ascenti G, Sofia C, Mazziotti S. , et al. Dual-energy CT with iodine quantification in distinguishing between bland and neoplastic portal vein thrombosis in patients with hepatocellular carcinoma. Clin Radiol 2016; 71 (09) 938.e1-938.e9
51 Qian LJ, Zhu J, Zhuang ZG. , et al. Differentiation of neoplastic from bland macroscopic portal vein thrombi using dual-energy spectral CT imaging: a pilot study. Eur Radiol 2012; 22 (10) 2178-2185
52 Gordic S, Puippe GD, Krauss B. , et al. Correlation between dual-energy and perfusion CT in patients with hepatocellular carcinoma. Radiology 2016; 280 (01) 78-87
53 Dai X, Schlemmer H-P, Schmidt B. , et al. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Radiol 2013; 82 (02) 327-334
54 Lee J-A, Jeong WK, Kim Y. , et al. Dual-energy CT to detect recurrent HCC after TACE: initial experience of color-coded iodine CT imaging. Eur J Radiol 2013; 82 (04) 569-576
55 Thaiss WM, Haberland U, Kaufmann S. , et al. Iodine concentration as a perfusion surrogate marker in oncology: Further elucidation of the underlying mechanisms using volume perfusion CT with 80 kVp. Eur Radiol 2016; 26 (09) 2929-2936
56 Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 2009; 47 (01) 161-178
57 Sahani DV, Holalkere N-S, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology 2007; 243 (03) 736-743
58 Ippolito D, Sironi S, Pozzi M. , et al. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol 2008; 15 (07) 919-927
59 Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008; 13 (02) 120-125
60 Chen BB, Hsu CY, Yu CW. , et al. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol 2017; 27 (07) 3069-3079
61 Messiou C, Orton M, Ang JE. , et al. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. Radiology 2012; 265 (02) 426-436
62 Wang Q, Shi G, Wang L, Liu X, Wu R. Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study. Br J Radiol 2014; 87 (1035): 20130695
63 Hsu C-Y, Shen Y-C, Yu C-W. , et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011; 55 (04) 858-865
64 Lassau N, Koscielny S, Chami L. , et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology 2011; 258 (01) 291-300
65 Zocco MA, Garcovich M, Lupascu A. , et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol 2013; 59 (05) 1014-1021
66 Frampas E, Lassau N, Zappa M, Vullierme M-P, Koscielny S, Vilgrain V. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. preliminary results. Eur J Radiol 2013; 82 (05) e205-e211
67 Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol 2003; 45 (03) 169-184
68 Taouli B, Koh D-M. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254 (01) 47-66
69 Baliyan V, Das CJ, Sharma R, Gupta AK. Diffusion weighted imaging: Technique and applications. World J Radiol 2016; 8 (09) 785-798
70 Heijmen L, Ter Voert EEGW, Nagtegaal ID. , et al. Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol 2013; 23 (03) 748-756
71 Galbán CJ, Hoff BA, Chenevert TL, Ross BD. Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed 2017;30(3)
72 Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging 2012; 35 (02) 257-279
73 Anzidei M, Napoli A, Zaccagna F. , et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr 2011; 35 (06) 690-696
74 Schraml C, Schwenzer NF, Martirosian P. , et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009; 193 (04) W301-7
75 Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology 2014; 272 (02) 417-426
76 Granata V, Fusco R, Catalano O. , et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs: the role of intravoxel incoherent motion in diffusion-weighted imaging. PLOS ONE 2015; 10 (11) e0142876
77 Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl. 01) 122S-150S
78 Hellman RS, Krasnow AZ, Sudakoff GS. Positron emission tomography for staging and assessment of tumor response of hepatic malignancies. Available at: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-2006-939838 . Accessed March 26, 2017
79 Ahn SJ, Park M-S, Kim KA. , et al. ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One 2013; 8 (08) e71571
80 Song MJ, Bae SH, Yoo IeR. , et al. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18 (25) 3215-3222
81 Salem N, Kuang Y, Corn D. , et al. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol 2011; 13 (01) 140-151
82 Torizuka T, Tamaki N, Inokuma T. , et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35 (12) 1965-1969
83 Kuehl H, Stattaus J, Hertel S. , et al. Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours–a single-centre experience. Clin Oncol (R Coll Radiol) 2008; 20 (03) 234-240
84 Kim BK, Kang WJ, Kim JK. , et al. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011; 117 (20) 4779-4787
85 Qayyum A. MR spectroscopy of the liver: principles and clinical applications. Radiographics 2009; 29 (06) 1653-1664
86 Maris JM, Evans AE, McLaughlin AC. , et al. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N Engl J Med 1985; 312 (23) 1500-1505
87 Li C-W, Kuo YC, Chen C-Y. , et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med 2005; 53 (04) 770-776
88 Wu B, Peng W-J, Wang P-J. , et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J 2006; 21 (04) 258-264
89 Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind J, Kamel IR. Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr 2011; 35 (02) 167-173
90 Kuo Y-T, Li C-W, Chen C-Y, Jao J, Wu D-K, Liu G-C. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging 2004; 19 (05) 598-604
91 Gonzalez-Guindalini FD, Botelho MPF, Harmath CB. , et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 2013; 33 (06) 1781-1800
92 Pepin KM, Chen J, Glaser KJ. , et al. MR elastography derived shear stiffness--a new imaging biomarker for the assessment of early tumor response to chemotherapy. Magn Reson Med 2014; 71 (05) 1834-1840
93 Xie M, Zhang X, Jia Z, Ren Y, Wang W. Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma. Oncol Lett 2014; 8 (04) 1652-1656
94 Kim BK, Kim SU, Kim M-J. , et al. Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 2013; 19 (06) 1503-1511
95 Bargellini I, Scionti A, Mismas V. , et al. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?. Oncology 2014; 86 (04) 191-198
96 Welsh JL, Bodeker K, Fallon E, Bhatia SK, Buatti JM, Cullen JJ. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. Am J Surg 2012; 204 (05) 580-585
97 Sacco R, Faggioni L, Bargellini I. , et al. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. Dig Liver Dis 2013; 45 (09) 776-781